Learning Objectives:

1.    Treatment of Severe Hypercholesterolemia: What have We Learned Over The Past Five Decades and  How Successful Have We Been
2.    What Are The Impediments To Guideline Directed Pharmacologic Lowering of LDL-C of 190 mg/dl or Greater
3.    Review The Pharmacotherapeutic Trajectory Of LDL-C; From Statins, to Ezetimibe to PCSK-9 Drugs:  Antibodies and SiRNA

Faculty Disclosure:

Neil Stone, MD, Presenter, has no relevant financial relationships to disclose.

Faculty does not plan to discuss the uses of an investigational product.